Trial Profile

Evaluation of Rapid Virological Response in HCV [hepatitis C virus] Patients Treated With PegIntron and Ribavirin - APEGIN Trial

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peginterferon alfa-2b (Primary) ; Peginterferon alfa-2b/ribavirin (Primary) ; Ribavirin (Primary)
Indications Hepatitis C
Focus Therapeutic Use
Acronyms APEGIN
Sponsors Merck Sharp & Dohme Corp.; Schering-Plough

Most Recent Events

16 Dec 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
16 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
28 Aug 2009 Planned end date changed from Jul 2009 to Oct 2009 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com